-
8/13/2019 Gudjonsson JE
1/3
1. Gudjonsson JE, Elder JT. Psoriasis. Dalam: Wolff K, Goldsmith
LA, Katz SI, GilchrestBA, Paller AS, Leffell DJ, editor.
Fitzpatricks Dermatology in General Medicine. Edisi
ke-7. New York. McGraw-Hill;2008. h.169-193.
2. Langley R, Krueger G, Griffiths C. Psoriasis: epidemiology,
clinical features, and qualityof life. Ann Rheum Dis. 2005;64:ii18-
ii23.
3. Neimann A, Porter S, Gelfand J. The epidemiology of
psoriasis. Expert Rev. Dermatol.2006;1(1), 63-75.
4. Damasiewicz A, Kuda B. Hormonal factors in etiopathogenesis
of psoriasis. Pol MerkurLekarski. 2007;22(127):75-8.
5. Foitzik K, Langan E, Paus R. Prolactin and the skin: A
dermatological perspective on anancient pleiotropic peptide
hormone. Journal of investigative dermatology
2009;129:1071-87.
6. Guyton A, Hall J. Hormon-hormon hipofisis dan pengaturannya
oleh hipotalamus. BukuAjar Fisiologi Kedokteran. Edisi ke-11.
Indonesia. EGC;2006. h.964-991.7. Freeman E, Kanyicska B, Lerant A.
Prolactin: structure, function, and regulation of
secretion. Physiological reviews 2000;80:4.
8. Yuan L, Lee Y. Prolactin modulation of immune and
inflammatory response.Endocrinology 2002;57:435-55.
9. Weber G, Neidhardt M, Frey H, Galle K, Geiger A. Treatment of
psoriasis withbromocriptin. Arch Dermatol Res. 1981;271:4379
10.Dunna SF, Finlay AY. Psoriasis, improvement during and
worsening after pregnancy. BrJ Dermatol.1989;120:58411.Giasuddin
AS, El-Sherif AI, El-Ojali SI. Prolactin: does it have a role in
the pathogenesis
of psoriasis?. Dermatology 1998;197:11922
12.Azzizadeh M, Malek M, Amiri M. Does prolactin indicate
severity of psoriasis?. Iranianjournal of dermatology
2009;12:3.
13.Dilme E, Martin G, Regana M. Serum prolactin levels ini
psoriasis and correlation withcutaneous disease activity. Clinical
and experimental dermatology 2010;36:29-32.
14.Sanchez RM, Umbert MP. Psoriasis in association with
prolactinoma: three cases. Br JDermatol. 2000;143:8647
15.Gorpeligolu C, Gungor E, Alli N. Is prolactin involved in
etiopathogenesis of psoriasis? JEur Acad Dermatol Venereol.
2008;22:1135-6.
16.Das R, Jain A, Ramesh V. Current concepts in pathogenesis of
psoriasis. Indian JDermatol. 2009;54(1):7-12.
17.Blauvelt A. New concept in the pathogenesis and treatment of
psoriasis: key roles forIL-23, IL-17A and TGF-1. Expert Rev.
Dermatol. 2007;2(1), 69-78
18.Bettina M, Vavricka P, Guitart J. Diagnostic evaluation.
Psoriatis and Psoriatic Arthritis-An Integrated Approach. Edisi
ke-1. New York. Springer;2005. h.83-91.
-
8/13/2019 Gudjonsson JE
2/3
19.Lisi P. Differential diagnosis of psoriasis. Reumatismo
2007;59:5660.20.Lionel F. Differential diagnosis. An Atlas of
Psoriasis. Edisi ke-2. London. Taylor &
Francis;2004. h.67-69.
21.Meier M, Sheth P. Clinical spectrum and severity of
psoriasis. Curr Probl Dermatol.Basel. 2009;38:120.
22.Feldman S, Krueger G. Psoriasis assesment tools in clinical
trial. Ann Rheum. Dis.2005;64:ii65-ii68.
23.Kenneth B. Clinical outcome measurements. Psoriatis and
Psoriatic Arthritis- AnIntegrated Approach. Edisi ke-1. New York.
Springer;2005. h.125-128.
24.Bonifati C, Berardesca E. Clinical outcome measures of
psoriasis. Reumatismo 2007;59:64-67.
25.Traub M, Marshall K. Psoriasis pathophysiology, conventional
and alternative approachesto treatment. Alternative Medicine Review
2007;12:319-30.
26.Reich K, Mrowietz U. Treatment goal in psoriasis. JDDG.
2007;5:566574.27.Sullivan J. Treatment for severe psoriasis. Aust
Prescr. 2009;32:1418.28.Harvey J, Guyda, Friesen H. Serum prolactin
levels in humans from birth to adult life.
Pediat. Res.1973;7:534-40.
29.Frantz AG. Prolactin. N Engl J Med. 1978;298:
201207.30.Franklin Scientific Projects Ltd. Normal and pathological
prolactin levels. Clear
Perspectives 1996;3:1-4.
31.Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine
circuitry of the brainskinconnection. Trends Immunol.
2006;27:329.
32.Girolomoni G, Phillips JT, Bergstresser PR. Prolactin
stimulates proliferation of culturedhuman keratinocytes. J Invest
Dermatol. 1993;101:2759.
33.Yu-Lee L. Stimulation of interferon regulatory factor-1 by
prolactin. Lupus 2001;10:6919.
34.De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella
A. Prolactin andautoimmunity. Pituitary 2005;8:2530.
35.Biswas R, Roy T, Chattopadhyay U. Prolactin induced reversal
of glucocorticoidmediated apoptosis of immature cortical thymocytes
is abrogated by induction of tumor. J
Neuroimmunol. 2006;171:12034.
36.Carreno PC, Jimenez E, Sacedon R, Vicente A, Zapata AG.
Prolactin stimulatesmaturation and function of rat thymic dendritic
cells. J Neuroimmunol. 2004;153:8390.
37.Matera L, Mori M, Galetto A. Effect of prolactin on the
antigen presenting function ofmonocyte-derived dendritic cells.
Lupus 2001;10:72834.
-
8/13/2019 Gudjonsson JE
3/3
38. Sun R, Li AL, Wei HM, Tian ZG. Expression of prolactin
receptor and response to prolactin
stimulation of human NK cell lines. Cell Res. 2004;14:6773 39.
Malaguarnera L, Imbesi R, Di Rosa M,
Scuto A et al. Action of prolactin, IFN-gamma, TNF-alpha and LPS
on heme oxygenase-1 expression
and VEGF release in human monocytes/macrophages. Int
Immunopharmacol. 2005;5:145869. 40.
Kanda N, Watanabe S. Prolactin enhances interferon- induced
production of CXCL9, CXCL10, and
CXCL11. Endocrinology 2007;148:231725. 41. Kanda N, Shibata S,
Tada Y et al. Prolactin enhances
basal and IL- 17 induced CCL20 production by human
keratinocytes. Eur J Immunol. 2009;39(4):996-
1006. 42. Murase J, Chan K, Garite T et al. Hormonal effect of
psoriasis in pregnancy and post
partum. Arch Dermatol. 2005;141:601-606. 43. Raychaudhuri S,
Navare T, Gross J et al. Clinical
course of psoriasis during pregnancy. International Journal of
Dermatology 2003;42:518520. 44.
Griffiths CE, Katsambas A, Dijkmans BA et al. Update on the use
of ciclosporin in immune-mediated
dermatoses. Br J Dermatol. 2006;155:116. 45. Suite M. The
epidemiology of psoriasis in a
dermatology clinic in a general hospital in port of Spain,
Trinidad and Tobago, West Indies. West
Indian Med J. 2006;55(6):1. 46. Naldi L. Epidemiology of
psoriasis.Curr Drug Target Inflamm Allergy.
2004;3(2):121-8. 47. Fatani MI, Abdulghani MH, Al-Afif KA.
Psoriasis in the eastern saudi arabia.Saudi Med J.
2002;23(2):213-7. 48. Dogra S, Yadav S. Psoriasis in India:
prevalence and pattern.
Indian J Dermatol Venereol Leprol 2010;76:595-60. 49. Mabuchi T,
Yamaoka H, Kojima T et al.
Psoriasis affects patient quality of life more seriously in
female than male in Japan. Tokai J Exp Clin
Med. 2012;37(3):84-8. 50. Gupta MA, Gupta KA. Age and gender
differences in the impact of
psoriasis on quality of life. Int J Dermatol. 1995;34:700-703.
51. Jacobson CC, Kimball AB.
Epidemiology. Dalam: Kenneth B, editor. Psoriasis and Psoriatic
Arthritis- An Integrated Approach.
Edisi ke-1. New York. Springer;2005. h.125-128. 52. Inerot A,
Enerback C, Enlund et al. Collecting a
set of psoriasis family material through a patient organization;
clinical characterization and presence
of additional disorders. BMC Dermatology. 2005;5(10):1-8.
